Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries

Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.

Across several continents, infecting mosquitoes with bacteria results in dramatic drops in dengue illness, trials show

Indonesia saw a 76% drop in dengue infections in the part of Indonesia where the mosquitoes were released. In Brazil, treated neighborhoods in Rio de Janeiro saw rates of dengue infections fall by 70%, and infections with chikungunya was 75% lower. North Queensland, Australia, hasn’t had a dengue in five years, and there has been a 96% reduction in locally acquired dengue infections.